Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

AITokenPostKorean, translatedFiled 41 h ago

Merck and Isomorphic Labs to discover AI anticancer drug candidates... Merck to handle subsequent development

Original headline머크·아이소모픽랩스, AI 항암 후보물질 발굴…후속 개발은 머크

Open the sourceReported by TokenPost, tokenpost.kr, 19 November 2026, by 서지우

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Merck ($MRK) and Isomorphic Labs have launched an AI-driven research collaboration to discover small-molecule drug candidates against a single cancer-related target, using Isomorphic's IsoDDE drug-design engine alongside some of Merck's proprietary data. The deal is a research-stage candidate-discovery effort rather than a readout of clinical efficacy or trial results. Isomorphic will receive an upfront payment plus milestone payments tied to research, development, regulatory and commercialization goals, and tiered royalties on net sales. Merck takes over preclinical and clinical development, manufacturing and commercialization of any resulting candidates. The partnership matters as a further validation of AI-based drug design by a major pharma player; next milestones would be nomination of a development candidate and progression into preclinical work.

Muhabbit's AI wrote this summary in its own words from TokenPost's report and translated it from Korean. It can get details wrong, so check the source.

Named in this story

Isomorphic Labs, Merck (MRK), IsoDDE

A linked name opens that asset's sentiment page.